ASN​ 2025 6 - 9 November 2025

Discordance between eGFRcystatin C and eGFRcreatinine and cardiovascular risk in the FLOW trial  

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Chronic Kidney Disease
Congress oral presentation
GLP-1 RA
Semaglutide
PHASE 3 (RCT)